GENEVA: The WHO today added 36 new drugs to the list of essential medicines , including groud-breaking new treatment for hepatitis C and multi-drug resistant tuberculosis (TB), but some experts said prices needed to fall to make them accessible to patients in poorer countries.The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.The WHO's Model List of Essential Medicines (EML), which is updated every two years, is used by governments around the world to help determine which treatments they should make available.The WHO Expert Committee considered 77 applications and included 15 to the core list and 21 to the complementary list of EML, including five products for hepatitis C, four to target multi-drug resistant TB and 16 new medicines to the Essential Medicines for Children (EMLc) -- five to the core list and 11 to the complementary list.Medicine for treating hepatitis C include sofosbuvir and daclatasvir. Drugs for targetting multi-drug resistant TB included bedaquiline and delamanid.The core list represents the minimum medicine list of a basic health care system and the complementary list represents essential medicines for priority diseases.WHO EML and EMLc list has a knock on effect on national governments where member states are expected to bring their national list in line with the WHO list."When new effective medicines emerge to safely treat serious and widespread diseases, it is vital to ensure that everyone who needs them can obtain them," said WHO Director General Margaret Chan in a statement.However, some of the medicines in the list are exorbitantly priced and beyond the reach of most patients.For instance, the price of Gilead's sofosbuvir, which is in the revised WHO EML, to cure hepatitis C, has been the subject of fierce debate with its USD 1000 a pill price tag.